<?xml version="1.0" encoding="UTF-8"?>
<p>Patients with clinically suspected NSCLC are eligible for this study if they meet the following criteria. The inclusion criteria are as follows: (1) age ≥20 years; (2) Eastern Cooperative Oncology Group performance status, 0–2; (3) clinical stage IA–IIIA; (4) radiologically diagnosed invasive lung tumour with a solid component of ≥1.0 cm visualised by thin-section CT; (5) complete resection, including mediastinal lymph node dissection or sampling is planned; (6) neutrophil count ≥1500 µL; (7) haemoglobin ≥80 g/L; (8) platelet count ≥100 x 10
 <sup>9</sup>/L; (9) aspartate transaminase ≤80 IU/L and alanine transaminase 80 IU/L; (10) serum creatinine ≤1.5 mg/dL; (11) SpO
 <sub>2</sub> ≥92% (room air). The tumours are staged according to the eighth edition of the Union for International Cancer Control TNM Classification of Malignant Tumors.
 <xref rid="R33" ref-type="bibr">33</xref>
</p>
